Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAFV600E Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report-Reference-Cited by-同舟云学术

Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAF^V600E Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report

Published:2020-08 Issue: Volume:Volume 13 Page:7933-7939
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Ding Honggang,Zhuang Zhenjie,Xie Jingyi,Huang Haifu,Tao Zhigang,Liu Zhanhua

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference16 articles.

1. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

2. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

3. Defining the lethal subclone in metastatic lung cancer

4. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04

2. Allelic Context of EGFR C797X–Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes;Journal of Thoracic Oncology;2023-11

3. Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations;Anti-Cancer Drugs;2023-08-15

4. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M;Anti-Cancer Drugs;2022-12-23

5. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance;Journal of Hematology & Oncology;2022-12-08